GRAIL
GRALPre-clinicalGRAIL is a mission-driven company leveraging next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect cancer early when it may be more treatable. Its clinical program has enrolled over 300,000 participants, and its Galleri test is at the forefront of the MCED category. The company is publicly traded and is focused on commercializing Galleri, expanding clinical utility evidence, and pursuing partnerships to integrate its test into healthcare systems globally.
GRAL · Stock Price
Historical price data
AI Company Overview
GRAIL is a mission-driven company leveraging next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect cancer early when it may be more treatable. Its clinical program has enrolled over 300,000 participants, and its Galleri test is at the forefront of the MCED category. The company is publicly traded and is focused on commercializing Galleri, expanding clinical utility evidence, and pursuing partnerships to integrate its test into healthcare systems globally.
Technology Platform
A multi-cancer early detection platform using next-generation sequencing of cell-free DNA methylation patterns combined with machine learning to identify a shared cancer signal and predict its tissue of origin from a single blood draw.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
GRAIL competes in the emerging Multi-Cancer Early Detection (MCED) market against companies like Exact Sciences, Guardant Health, Freenome, and Delfi Diagnostics. Its key differentiator is its extensive clinical evidence base, including the large, randomized NHS-Galleri trial, which provides a significant head start in demonstrating real-world utility to payers and clinicians.